Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results

Core Insights - Brii Biosciences reported strong execution and strategic progress in 2025, particularly in advancing its hepatitis B virus (HBV) portfolio towards higher functional cure rates [2][5] - The company maintains a strong cash position of US$276.1 million as of December 31, 2025, providing financial flexibility for its strategic priorities [4][15] - Brii Bio is focused on disciplined financial management and aligning management incentives with long-term shareholder interests [13][15] Clinical Program Updates - The company presented promising 24-week post end of treatment data from its Phase 2b ENSURE study, indicating the potential of BRII-179 to improve functional cure outcomes [2][6] - The ENHANCE study protocol was amended to evaluate a simplified triple combination regimen aimed at reducing treatment duration while maintaining efficacy, with results expected in 2H 2026 [2][10] - Ongoing studies (ENSURE, ENRICH, and ENHANCE) are fully enrolled, with data readouts anticipated to inform future registrational development decisions [10][14] Discovery Program Updates - Brii Bio has expanded its discovery efforts, establishing in-house capabilities and wet lab operations in Beijing and Shanghai to leverage China's drug discovery ecosystem [3][12] - The company announced a strategic out-licensing agreement with Joincare Group for the commercialization of soralimixin in Greater China, retaining rights outside this region [11][22] - Collaboration with OpenBench aims to utilize AI to accelerate discovery efforts, with updates expected throughout 2026 [11][12] Financial Performance - The company reported a loss of RMB224.1 million for the year ended December 31, 2025, a decrease of 56.3% compared to the previous year, primarily due to reduced fair value losses and lower operating expenses [15][22] - Administrative expenses decreased by 28.5% to RMB109.5 million, attributed to organizational optimization and adjustments in management compensation [15][22] - Research and development expenses were RMB212.9 million, down 14.8% from the previous year, reflecting a focus on prioritizing HBV programs [15][22]